Novel and emerging innate immune therapeutic targets for pancreatic cancer.

Expert Opin Ther Targets

a Department of Gastroenterology, Hepatology and Nutrition , The University of Texas MD Anderson Cancer Center, Houston , TX , USA.

Published: December 2018

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728222.2018.1538361DOI Listing

Publication Analysis

Top Keywords

novel emerging
4
emerging innate
4
innate immune
4
immune therapeutic
4
therapeutic targets
4
targets pancreatic
4
pancreatic cancer
4
novel
1
innate
1
immune
1

Similar Publications

Monocyte-cancer cell fusion is mediated by phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation.

PLoS One

January 2025

Division of Cell- and Neurobiology, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.

Emerging evidence suggests that fusion of cancer cells with leucocytes, such as macrophages, plays a significant role in cancer metastasis and results in tumor hybrid cells that acquire resistance to chemo- and radiation therapy. However, the precise mechanisms behind the leukocyte-cancer cell fusion remain unclear. The present in vitro study explores the presence of fusion between the monocyte cell line (THP-1) and the breast cancer cell line (MCF-7) in relation to the expression of CD36 and phosphatidylserine with and without treatment of these cells with ionizing radiation.

View Article and Find Full Text PDF

Antihypertensive effects of rice peptides involve intestinal microbiome alterations and intestinal inflammation alleviation in spontaneously hypertensive rats.

Food Funct

January 2025

Department of Nutrition and Food Hygiene, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.

Gut dysbiosis serves as an underlying risk factor for the development of hypertension. The resolution of this dysbiosis has emerged as a promising strategy in improving hypertension. Food-derived bioactive protein peptides have become increasingly more attractive in ameliorating hypertension, primarily due to their anti-inflammatory and anti-oxidant activities.

View Article and Find Full Text PDF

Intermediate Control: Unlocking Hitherto Unknown Reactivity and Selectivity in N-Conjugated Allenes and Alkynes.

Acc Chem Res

January 2025

Department of Chemistry and Chemistry Institution for Functional Materials, Pusan National University, Busan 46241, Republic of Korea.

ConspectusControlling selectivity through manipulation of reaction intermediates remains one of the most enduring challenges in organic chemistry, providing novel solutions for selective C-C π-bond functionalization. This approach, guided by activation principles, provides an effective method for selective functional group installation, enabling direct synthesis of organic molecules that are inaccessible through conventional pathways. In particular, the selective functionalization of N-conjugated allenes and alkynes has emerged as a promising research focus, driven by advances in controlling reactive intermediates and activation strategies.

View Article and Find Full Text PDF

Novel patterns in discrete Ikeda map: Quint points and complex non-quantum chirality.

Chaos

January 2025

School of Mechanical and Power Engineering, Zhengzhou University, Science Road 100, 450001 Zhengzhou, China.

In this paper, the complex and dynamically rich distribution of stable phases in the well-known discrete Ikeda map is studied in detail. The unfolding patterns of these stable phases are described through three complementary stability diagrams: the Lyapunov stability diagram, the isoperiod stability diagram, and the isospike stability diagram. The adding-doubling complexification cascade and fascinating non-quantum chiral pairs are discovered, marking the first report of such structures in discrete mapping.

View Article and Find Full Text PDF

Systems-level liquid biopsy in advanced prostate cancer.

Endocr Relat Cancer

January 2025

S Dehm, Masonic Cancer Center, University of Minnesota, Minneapolis, United States.

Treatment for castration-resistant prostate cancer (CRPC) primarily involves the suppression of androgen receptor (AR) activity using androgen receptor signaling inhibitors (ARSIs). While ARSIs have extended patient survival, resistance inevitably develops. Mechanisms of resistance include genomic aberrations at the AR locus that reactivate AR signaling, or lineage plasticity that drives emergence of AR-independent phenotypes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!